

Inclusive, Sustainable, Prosperous and Resilient Health Systems in Asia and the Pacific

INSPIRE Health Forum

7-11 July 2025 • A Hybrid Event



PARALLEL SESSION

#INSPIREhealth2025

Noncommunicable Diseases Innovation

Explore how digital and AI-driven innovations can increase and strengthen access, efficiency and equity in NCD care across Asia and the Pacific. The session will examine regional experiences and address implementation challenges, and highlight opportunities for scaling inclusive, technology-enabled solutions.

08 July 2025 • 01:15 - 02:30 PM

• Auditorium 4





Artificial Intelligence for Lung Health

ADB- INSPIRE 2025



qXR: Chest X-Ray AI


FDA 510(k) cleared for Breathing tubes

Hardware & PACS Agnostic

CE CE Class II B Certified

WHO Endorsed

- Detects & localizes 30+ chest abnormalities including lung nodules
- Prioritizes worklist for abnormal chest x-rays
- Generates AI Secondary Capture of chest x-ray
- Pre-populates editable Radiologist report



2000+

sites, deployed across 50+ countries

4.5Mn+

Scans training dataset

7.3Mn+

Scans processed annually


qLC: Qure's Lung Cancer Suite

IDENTIFY
With qXR
Chest X-ray AI

MEASURE
With qCT
Chest CT AI


MANAGE
With qTrack
Care-coordination platform

qXR-LN




Nodule detection on Chest X-rays

qCT



Lesion management on CTs


qTrack



F/up management App

Proprietary risk score for qXR - COPD


qXR – COPD risk score has been trained on X-rays with paired spirometry data and supplemented with associated radiological findings like Emphysema, Bronchitis and others

COPD associated radiological findings	Image
Flattened Diaphragms	
Air Bullae	
>10 posterior ribs in midclavicular line above diaphragm	
Hyperlucent lungs	
Reduced Broncho vascular Markings	

Training dataset

qXR – COPD tags	Ground truth	No. of scans
qXR – COPD proprietary risk score	Spirometry confirmation	25,342 Positive: 9,210 Negative: 16,132
qXR – COPD associated radiological findings	Radiology reports and Radiology annotations	Positive cases: 112,023 Negative cases/controls: 5M+

Region split of training dataset



Growing Partnership with AstraZeneca in Asia

Scale

Deploying qXR globally for **early-stage lung cancer detection** from CXRs

250

Sites

4M+

People Screened


6

Countries



LEIF JOHANSSONN
Chair, Astra Zeneca

As part of the EDISON Alliance's **1 Billion Lives Challenge**, AstraZeneca along with Qure.ai will be screening **5 million patients by 2025**



Regionwise split

Evidence

International region

54% PPV, 94% NPV

Caught with Qure.ai lung cancer product suite



International region

1 LC Patient / 1051 CXRs


Caught with Qure.ai lung cancer product suite

Data collected from 27 sites (6 nations)

Thailand

14 missed LC Patients

Originally missed on first chest x-ray



and more

Policy change

Qure.ai and AZ country teams have collaborated with country MOH bodies



Malaysia



Thailand

Closed ecosystems

Screening pilots

Nation wide adoption

Thank You!